Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

United Therapeutics (UTHR) EPS (Weighted Average and Diluted) (2016 - 2026)

United Therapeutics' EPS (Weighted Average and Diluted) history spans 17 years, with the latest figure at $7.69 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 23.83% to $7.69 in Q4 2025 year-over-year; TTM through Dec 2025 was $27.89, a 13.28% increase, with the full-year FY2025 number at $27.86, up 13.07% from a year prior.
  • EPS (Weighted Average and Diluted) hit $7.69 in Q4 2025 for United Therapeutics, up from $7.16 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for UTHR hit a ceiling of $7.69 in Q4 2025 and a floor of $0.61 in Q1 2021.
  • Historically, EPS (Weighted Average and Diluted) has averaged $4.87 across 5 years, with a median of $5.14 in 2022.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 80.45% in 2021 and later soared 724.59% in 2022.
  • Tracing UTHR's EPS (Weighted Average and Diluted) over 5 years: stood at $2.34 in 2021, then grew by 13.25% to $2.65 in 2022, then surged by 63.4% to $4.33 in 2023, then soared by 43.42% to $6.21 in 2024, then grew by 23.83% to $7.69 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for UTHR at $7.69 in Q4 2025, $7.16 in Q3 2025, and $6.41 in Q2 2025.